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In the current study we evaluated the effects of immunoproteasome inhibition using ONX 0914 (formerly
PR-957) to ameliorate graft-versus-host disease (GVHD). ONX 0914, an LMP7-selective epoxyketone inhibitor
of the immunoproteasome, has been shown to reduce cytokine production in activated monocytes and T cells
and attenuate disease progression in mouse models of rheumatoid arthritis, colitis, systemic lupus erythe-
matosus, and, more recently, encephalomyelitis. Inhibition of LMP7 with ONX 0914 in the B10.BR/CBAMHC-
matched/minor histocompatibility antigen (miHA)-disparate murine blood and marrow transplant (BMT)
model caused a modest but signiﬁcant improvement in the survival of mice experiencing GVHD. Concomitant
with these results, in vitro mixed lymphocyte cultures revealed that stimulator splenocytes, but not
responder T cells, treated with ONX 0914 resulted in decreased IFN-g production by allogeneic T cells in both
MHC-disparate (B10.BR anti-B6) and miHA-mismatched (B10.BR anti-CBA) settings. In addition, a reduction in
the expression of the MHC class Ierestricted SIINFEKL peptide was observed in splenocytes from transgenic
C57BL/6-Tg(CAG-OVA)916Jen/J mice exposed to ONX 0914. Taken together, these data support that LMP7
inhibition in the context of BMT modulates allogeneic responses by decreasing endogenous miHA presen-
tation and that the consequential reduction in allogeneic stimulation and cytokine production reduces GVHD
development.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Immunotherapy in the form of allogeneic blood and
marrow transplantation (allo-BMT) has proven to be one of
the few curative treatments for patients suffering from a
number of drug-resistant hematological malignancies. This
therapy exploits the broad donor T cell repertoire targeting
a diversity of deﬁned and undeﬁned allogeneic MHC anti-
gens, non-MHC minor histocompatibility antigens (miHAs)
derived from polymorphic intracellular proteins, and tumor-
speciﬁc antigens presented by both MHC class I and class II
molecules. Donor T cells play a central role in eliminatingdgments on page 1563.
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ty for Blood and Marrow Transplantation.residual tumor cells that persist after conditioning regimens.
However, they also facilitate patient immune reconstitution
via homeostatic proliferation and provide ﬁrst-line immu-
nity against opportunistic infections while de novo bone
marrowederived immune cells slowly emerge after trans-
plant. Although allo-BMT permits partial or complete
remission in signiﬁcant percentages of patients, it also comes
with its limitations; in particular, acute graft-versus-host
disease (GVHD) is a major cause of nonrelapse morbidity
and mortality, affecting 40% to 60% of allo-BMT patients and
accounting for 15% of deaths [1].
The proteasome is a large intracellular multicatalytic
protease complex responsible for degradation of intracellular
proteins and therefore critical for miHA presentation [2].
The 20S proteasome appears as a cylinder-like structure in
various eukaryotes, consisting of 4 rings with 7 subunits each
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the active centers of the 20S proteasome. In hematopoietic
cells and cells stimulated with IFN-g and tumor necrosis
factor-a (TNF-a), however, the catalytic subunits LMP2 (b1i),
MECL-1 (b2i), and LMP7 (b5i) replace the constitutive
subunits b1, b2, and b5 and are incorporated into the
immunoproteasome [2,4]. The immunoproteasome regu-
lates antigen presentation on MHC class I molecules, which
displays peptides for surveillance of pathogen-infected cells
by CD8þ T cells and shapes the repertoire of that T cell subset
in the thymus [4,5]. In addition to this role, the immuno-
proteasome also regulates cytokine production by immune
cells [4,6]. More recently, a number of studies have shown
that the immunoproteasome also plays a crucial role in
T cellemediated autoimmune diseases [3,6,7].
These results, together with preclinical GVHD studies
demonstrating the beneﬁcial effects of bortezomib [8-10], a
proteasome inhibitor extensively used for the treatment
ofmultiplemyeloma[11,12], led to thecurrentevaluationof the
immunoproteasome inhibitor ONX 0914 (formerly PR-957) to
ameliorate GVHD. ONX 0914, an LMP7-selective epoxyketone
inhibitorof the immunoproteasome,hasbeenshownto reduce
cytokine production in activated monocytes and T cells and
attenuate disease progression inmousemodels of rheumatoid
arthritis [7], colitis [6], systemic lupus erythematosus [13], and,
more recently, encephalomyelitis [3]. Inhibition of LMP7 with
ONX0914 in theB10.BR/CBAMHC-matched/miHA-disparate
murine BMT model caused a modest but signiﬁcant improve-
ment in the survival ofmice experiencing GVHD. Concomitant
with these results, in vitro mixed lymphocyte cultures (MLC)
revealed that stimulator splenocytes, but not responder
T cells, treated with ONX 0914 resulted in decreased IFN-g
productionbyallogeneic Tcells inbothMHC-disparate (B10.BR
anti-B6) andmiHA-mismatched (B10.BR anti-CBA) settings. In
addition, a reduction in the expression of the MHC class
Ierestricted SIINFEKL peptide was observed in splenocytes
from transgenic C57BL/6-Tg(CAG-OVA)916Jen/J mice exposed
to ONX 0914. These data suggested that, in the context of
GVHD, immunoproteasome inhibition via LMP7 likely modu-
lates donor T cell allogeneic responses primarily via down-
regulation of host antigen presentation of miHA, an effect
that preferentially impacted cytotoxic CD8þ T cell activity in
our BMT model.
METHODS
Mice
Breeding pairs of B10.BR-H-wk H2-T18a/SgSnJJrep (B10.BR), C57Bl/6J
(B6), and C57BL/6-Tg(CAG-OVA)916Jen/J mice were purchased from The
Jackson Laboratory (Bar Harbor, ME) and bred in our colony. Male CBA/J
(CBA) mice were purchased from The Jackson Laboratory and used as
recipients. All mice were housed in a sterile environment in microisolator
cages and given autoclaved food and acidiﬁed water (pH 2.5) ad libitum.
Both donor and recipient micewere used between 8 and 12weeks of age. All
protocols used in this study were approved by the Hackensack University
Medical Center’s Institutional Animal Care and Use Committee.
Flow Cytometry
Staining was performed using directly conjugated rateanti-mouse
mAbs (BD Pharmingen, San Jose, CA) diluted to 1:100 in FACS buffer (1% BSA
with 0.02% sodium azide in 1 PBS) directed to CD4 PE (clone RM4-5), CD8
PC5 (clone 53-6.7), and B220 FITC (clone RA3-6B2). Anti-H2Kb-SIINFEKL
mAb (clone eBio25-D1.16) was purchased from eBioscience (San Diego, CA).
The FC500 ﬂow cytometer (Beckman Coulter, Miami, FL) was used for all
acquisitions and analyses.
Preparation of Cells for GVHD Experiments
Donor lymphocytes were prepared from pooled RBC-lysed spleens and
lymph nodes enriched for T cells by a 37C incubation with anti-CD24 mAb
(J11d.2; 1:500) and guinea pig complement (C0) to deplete B cells. CD8þ Tcells were then depleted from the T celleenriched population using CD8þ
speciﬁc mAb (3.168; 1:100) to augment the CD4þ population. Anti-Thy1
mAb þ C0 treated bone marrow (ATBM) cells were produced from donor
mice by ﬂushing the bone marrow cells from the femurs, followed by
incubation with anti-Thy1 mAb (J1j; 1:100) and C’.
GVHD Experiments
CBA recipient mice were exposed to lethal irradiation (11 Gy, split dose,
4 hours apart) using a 137Ce source (Gammacell 40 Exactor; NDS Nordion,
Canada). Mice were then transplanted with 2  106 B10.BR ATBM cells alone
or in combination with 1  107 enriched B10.BR T cells. ONX 0914 was
administered i.v. for the day 0 to 2 treatment in our ﬁrst experiment and s.c.
for all subsequent treatments and experiments. Responses were comparable
by either administrative route, but multiday s.c. injections were technically
easier to perform. Mice were examined daily for morbidity and mortality
and weighed twice weekly.
ELISpot Assay
Millipore (Billerica, MA) 96-well multiscreen plates with Immobilon-P
membrane were coated with afﬁnity-puriﬁed anti-mouse IFN-g mAb (AN-
18; 10 mg/mL; eBioscience) at 4C overnight. Responder cell populations
were prepared by harvesting peripheral lymph nodes and enriching for T
cells by B cell depletion and, when necessary, CD8þ enrichment by CD4
depletion. RBC-lysed splenocytes were irradiated (15 Gy) and used as
stimulators. Compound treated groupswere incubated for 1 hour at 37C, 5%
CO2, with either .1% DMSO vehicle, 300 nM ONX 0914 (a LMP7-selective
concentration [7]) solubilized in .1% DMSO, or 125 nM PR-825 (a b5 sub-
unit selective concentration [6]) solubilized in .1% DMSO, followed by 3
washes with cRPMI before plating.
Coated ELISpot plates (Millipore, Billerica, MA) were washed and
blocked for 1 hour at 37C, 5% CO2 with cRPMI before plating the cells in an
R:S ratio of 1:2 in cRPMI (RPMI 1640 media [Mediatech, Herndon, VA]
containing 10% FBS [Hyclone, Logan, UT], 2 mM L-glutamine, penicillin [50
IU/mL[/streptomycin [50 mg; Mediatech] and 2-ME) for 48 hours at 37C, 5%
CO2. After incubation, the plates were washed with 1 PBS containing .01%
Tween-20 (Sigma-Aldrich, St. Louis, MO).
Biotinylated anti-mouse IFN-g mAb (clone R4-6A2; 1 mg/mlL; eBio-
science) was incubated for 2 hours in the dark at room temperature,
followed by Tween-20 washes as described above. The plate was then
incubated with a 1:1000 dilution of Avidin-HRP (eBioscience) in 1 PBS
for 1 hour at room temperature. 3,30-Diaminobenzidine tetrahydro-
chloride (Sigma-Aldrich) substrate solution was used to develop the plate
for 10 minutes at room temperature, followed by washing and spot
enumeration using an Immunospot plate reader, software version 3.2
(Cellular Technology Limited, CTL, Shaker Heights, OH). Spot counts from
a minimum of 4 wells per experiment were averaged and statistical
analysis performed. Mouse strains and T cell populations are indicated for
each experiment in the appropriate ﬁgure legend, as cited below.
Antigen Presentation Assay
Spleens from C57BL/6-Tg(CAG-OVA)916Jen/J mice were harvested
and RBCs lysed. Splenocytes were either left untreated or treated with .1%
DMSO or 300 nM ONX in .1% DMSO for 1 hour at 37C, 5% CO2. After
treatment, cells werewashed 3 times and platedwith cRPMI at 37C, 5% CO2.
SIINFEKL expression was analyzed by ﬂow cytometry at 24 and 48 hours
post-treatment.
Histopathology
At days 5 and 12 post-transplantation, GVHD target organs (liver,
spleen, small and large intestine) were harvested into 4% para-
formaldehyde, which was washed and replaced with 70% ethanol after 24
hours. Samples were sent to the Digital Imaging and Histology Core
at Rutgers-NJMS Cancer Center (Newark, NJ) for parafﬁn embedding,
sectioning, slide preparation, and H & E staining. GVHD scoring was
performed by a veterinary pathologist. A semiquantitative scaling from
0 to 5 was implemented based on histopathological ﬁndings, as follows:
normal ¼ 0, minimal ¼ 1, mild ¼ 2, moderate ¼ 3, moderately severe/
marked ¼ 4, and severe/high ¼ 5. A half score was considered for the
ﬁndings that fell between severities described earlier. Cumulative histo-
pathology scores were calculated based on the sum of individual changes
of various parameters in each organ (villous blunting, crypt cell hyper-
plasia, crypt cell apoptosis, and mucosal and submucosal inﬂammation in
the small intestine; Goblet cell depletion, crypt cell hyperplasia, crypt cell
apoptosis, and mucosal and submucosal inﬂammation in large intestine;
and bile duct degeneration and inﬂammation in liver). Each experiment
consisted of 3 to 4 mice per group. Images were visualized using an
Olympus BX61 microscope (Waltham, MA) and images captured with
CellSense Standard software (Olympus, Waltham, MA).
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A pilot experiment was conducted to evaluate and compare the prolif-
erative capacity of donor T cells in recipient mice treated with either ONX
0914or bortezomib (Supplemental Figure1). To this end, B10.BR cells isolated
fromperipheral lymph nodeswere labeledwith 5 mMof the cell proliferation
dyeeFluor 670 (eBioscience) according to themanufacturer’s instructions. B6
recipient mice (3 to 4 mice per group) were exposed to lethal irradiation (11
Gy, split dose, 4 hours apart) and inoculated with 2  107 eFluor670-labeled
B10.BR T cells and treated on days 0, 1, and 2 with either ONX 0914, borte-
zomib, or vehicle (Captisol; Ligand Technology, La Jolla, CA). On day 4 mice
were killed, and splenic cells were collected for ﬂow cytometric analyses.
Statistical Analyses
For multiple comparisons (>2 groups), 1-way repeated-measures
analysis of variance (ANOVA) was conducted, followed by Tukey’s multiple
comparison test on individual pairs to determine signiﬁcant differences
among groups when ANOVA test was statistically signiﬁcant. Student t-test
was used when comparing 2 groups. A P < .05 was considered signiﬁcant.
Prism software (GraphPad, La Jolla, CA) was used to perform analyses.
RESULTS
LMP7-Selective Epoxyketone Inhibition Using the
Immunoproteasome Inhibitor ONX 0914 Prolongs the
Survival of Transplanted Mice in the B10.BR into CBA
miHA-Disparate BMT Model
The potential use of ONX 0914 as an immunothera-
peutic agent to ameliorate GVHD was evaluated in the
MHC-matched/miHA-disparate CD8þ T cellemediated
B10BR/CBA murine BMT model. ONX 0914 was adminis-
tered at a concentration of 8 mg/kg (a dose that prefer-
entially targets LMP7 and to a lesser degree LMP2) on days
0, 1, and 2 post-BMT either in full dose (once a day), split
dose (twice a day, 6 hours apart), or split dose on days 0, 1,
2, 3, and 4. ONX 0914 (days 0, 1, and 2, full dose) resulted in
a modest but statistically signiﬁcant prolongation of the
survival of treated mice compared with that of the non-
treated (GVHD) recipients (Figure 1A; ONX 0914 median
survival time (MST) ¼ 24 days versus GVHD MST ¼ 18.5
days; P ¼ .023). No other regimen yielded statistically
signiﬁcant improvement in the MST of GVHD mice. WeightFigure 1. Effect of ONX 0914 on the survival rate of transplanted mice in the B10.BR
lethal irradiation (11 Gy, split dose) and transplanted with 2  106 B10.BR anti-Thy
enriched B celledepleted B10.BR T cells (GVHD control and ONX 0914 treated groups)
bolus (full dose, 1/d, or split dose, 2/d, 6 hours apart at 8 mg/kg) on days 0, 1, and 2
Shown are 2 pooled experiments with 9 to 3 mice per group. Statistical signiﬁcance b
GVHD versus ONX 0914 (full dose, d0-2), *P ¼ .023. Additionally, ATBM versus GVHD o
or any of the ONX 0914 treated groups, P < .01. (B) Percent of initial body weight of co
with that of best ONX 0914 regimen (full dose, d0-2). The mean  standard deviation p
to the mean weight of the group on d0.loss was monitored in survival experiments as an indicator
of GVHD severity (Figure 1B). No statistical differences
were found between GVHD and ONX 0914 groups or be-
tween ATBM and ATBM þ ONX 0914 recipient mice.ONX 0914 Preferentially Affects Stimulator Cells and
Modulates the Production of INF-g by Responder T Cells
in MLCs of MHC-Mismatched and miHA-Disparate BMT
Models
To better understand the mechanisms by which immu-
noproteasome inhibition improved the survival of trans-
planted mice undergoing GVHD, we examined the effect
of ONX 0914 treatment in MLC from the B10.BR anti-B6
MHC-mismatched and the B10.BR anti-CBA miHA-disparate
BMT models. In brief, for the B10.BR anti-B6 model, B6
stimulator (S) splenocyte populations were either exposed to
irradiation (15 Gy) and treated with vehicle (DMSO, .1%) or
ONX 0914 (300 nM) or treated before irradiation, as indi-
cated (Figure 2A and B). We chose to evaluate radiation
timing (ie, before or after treatment) to better recapitulate
the conducted in vivo experiments where mice received
treatment post-irradiation and to determine if treatment
pre-irradiation could have been beneﬁcial to their survival.
After treatment, cells were washed 3 times with PBS and
plated along with B10.BR responder (R) T cells as described,
at an R:S ratio of 1:2 (2  105 to 4  105). For some experi-
mental conditions, responder T cells were also treated with
ONX 0914 (300 nM) for 1 hour and washed 3 times with PBS
before plating (Figure 2A and B).
The results from these experiments indicate the
following. First, treatment of B6 stimulator cells with ONX
0914 signiﬁcantly decreased the production of IFN-g by
alloreactive B10.BR responder T cells, irrespective of irradi-
ation order (P < .05 before irradiation and P < .05 after
irradiation). Second, ONX 0914 treatment of only B10.BR
responder T cells had no effect on their IFN-g productioninto CBA miHA-disparate BMT model. (A) CBA recipient mice were exposed to
1 mAb þ C0 treated bone marrow (ATBM) cells in combination with 1  107
. ONX 0914 was dissolved in Captisol and administered to mice as an s.c. or i.v.
(d0-2) or days 0, 1, 2, 3, and 4 (d0-4) (split dose, 2/d, 6 hours apart) post-BMT.
etween survival curves was determined using the log-rank (Mantel-Cox) test.
r any of the ONX 0914etreated groups, P < .01, ATBM þ ONX 0914 versus GVHD
ntrol ATBM, ATBM þ ONX 0914 (split dose, d0-4), and GVHD groups compared
ercent initial body weight of surviving mice in each group was derived relative
Figure 2. Effect of ONX 0914 on the production of IFN-g by allogeneic Tcells inMHC-mismatched B10.BR anti-B6MHCMLCs. Lymph node cells isolated from B10.BRmice
were Tcell enriched by B cell depletion andused as responders (R) inMLCs. Splenocytes fromB6micewere prepared as described and exposed to irradiation (15 Gy) before
use as stimulators (S). MLCs were plated at a, R:S ratio of 1:2 (2 105 to 4  105) and incubated for 48 hours before measuring INF-g production by responder cells using
ELISpot assays. ONX0914 (300 nM)was solubilized in a DMSO vehicle (.1%) and stimulators, responders, or both responders and stimulatorswere treated for 1 hour at 37C
eitherbeforeorafter irradiation (rad)andcomparedwithvehicle (DMSO) treatment.All cellswerewashed3timeswithcRPMI-1640mediabeforeplating. (A)Representative
wells showing spot counts of IFN-geproducing cells. (B) IFN-g spot counts under different culture conditions as speciﬁed on the x-axis. Experimentswere repeated 3 times
with 4 to 8 wells per experiment, and data are from a representative experiment. Statistical analyses were performed using a nonparametric Mann-Whitney U test to
compare spot counts betweenDMSO andONX 0914 treatments under the speciﬁed conditions. *P< .05. The percent decrease in spot counts betweenDMSO and ONX 0914
treatments was as follows: I ¼ 59%, II ¼ 53%, III ¼ N/A, III ¼ 59%, and IV ¼ 45%. (C) IFN-g spot counts after a 48-hour MLC (R:S ratio of 1:2 [3  105 to 6  105]) where B6
stimulatorswere pretreated for 24 hours (at 37C and5%CO2)with eitherONX0914 (300 nM) or vehicle (DMSO, .1%) beforeplating. Data are results of 1 experimentwith12
wells. The Mann-Whitney U test was used to compare spot counts between DMSO and ONX 0914 treatments. ****P < .0001. The percent decrease in spot counts between
DMSO and ONX 0914 treatments was 77%.
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counts in ONX 0914etreated cells). Third, treatment of both
responder and stimulator cells, before or after irradiation,
resulted in a signiﬁcant count reduction of approximately
60% (P < .05), which was equivalent to that of treatment of
stimulators alone.
Next, we tested the effects of incubating B6 splenocyte
cells for a period of 24 hours after the 1-hour exposure to
either vehicle or ONX 0914. Although a signiﬁcant reduction
in the number of spot counts was also observed as a result
of this culture approach (Figure 2C, P < .0001), the 24-hour
interval did not completely abrogate the production of
IFN-g by B10.BR allogeneic T cells (ONX 0914 presented with
107 spot counts versus 470 spots with DMSO-treated sple-
nocytes; a 77% decrease).
Because other proteasome inhibitors such as borte-
zomib can mediate equivalent inhibition of the b5 and
LMP7 subunits, we investigated the speciﬁcity of the
observed response to the inhibition of the LMP7 subunit by
comparing the effects of the selective b5 inhibitor PR-825
with that of ONX 0914 (Figures 3 and 4) on the production
of IFN-g by allogeneic T cells. The results of these assays
indicated that PR-825 had no effect on either the MHC-
mismatched (Figure 3) or miHA-disparate (Figure 4) BMTFigure 3. Comparison of ONX 0914 and PR-825 effects on the production of
IFN-g by allogeneic T cells in MHC-mismatched B10.BR anti-B6 MHC MLCs.
Lymph node cells isolated from B10.BR mice were T cell enriched by B cell
depletion and used as responders (R) in MLCs. Splenocytes from B6 mice were
prepared as described and exposed to irradiation (15 Gy) before use as stim-
ulators (S). MLCs were plated in an R:S ratio of 1:2 (3  105 to 6  105 cells)
and incubated 48 hours at 37C before measuring INF-g production by
responder cells using ELISpot assays. B6 stimulators were incubated for 1 hour
at 37C in vehicle (DMSO, .1%), ONX 0914 (300 nM), or PR-825 (125 nM) and
washed 3 times with cRPMI-1640 before plating. Experiments were repeated 3
times with 4 to 8 wells per experiment, and data are from a representative
experiment. Statistical analysis was performed using 1-way ANOVA to
compare IFN-g spot counts between DMSO, ONX 0914, and PR-825 treatments,
followed by Tukey’s multiple comparison test on individual pairs when
ANOVA test was statistically signiﬁcant (P < .05). ****P < .0001.
Figure 4. Comparison of ONX 0914 and PR-825 effects on the production of
IFN-g by allogeneic T cells in miHA-mismatched BB10.BR anti-CBA MLCs.
Enriched T cells (B cell depleted) or CD8þ T cells (B cell and CD4 depleted) from
B10.BR mice were used as responders (R) in MLCs. Splenocytes from CBA mice
were prepared as described and exposed to irradiation (15 Gy) before use as
stimulators (S). MLCs were plated in an R:S ratio of 1:2 (3  105 to 6  105
cells) and incubated 48 hours at 37C before measuring INF-g production by
responder cells using ELISpot assays. CBA stimulators were incubated for 1
hour at 37C in vehicle (DMSO, .1%), ONX 0914 (300 nM), or PR-825 (125 nM)
and washed 3 times with cRPMI-1640 before plating. Experiments were
repeated 3 times with 4 to 8 wells per experiment, and data are from a
representative experiment. Statistical analysis was performed using 1-way
ANOVA to compare IFN-g spot counts between DMSO, ONX 0914, and
PR-825 treatments, within the enriched T cell or CD8þ T cell group, followed by
Tukey’s multiple comparison test on individual pairs when ANOVA test was
statistically signiﬁcant (P < .05). **P < .01, ***P < .001, ****P < .0001.tested models. Furthermore, because B10.BR/CBA GVHD
is dominantly mediated by CD8þ T cells [14], we also con-
ducted MLC and ELISpot assays to determine IFN-g pro-
duction by enriched CD8þ B10.BR T cells against CBA
stimulators treated with either DMSO, ONX 0914, or PR-825
(Figure 4). Once more, ONX 0914 signiﬁcantly reduced the
spot counts (P values in ﬁgure legends), whereas PR-825
had no effect.ONX 0914 Reduces the Production of IFN-g by CD3/CD28
Polyclonally Stimulated T Cells
To determine the effect of ONX 0914 on T cell activation,
we polyclonally stimulated ONX 0914etreated B10.BR T cells
with antibodies directed to CD3 and CD28. Although we
found that direct treatment of T cells with ONX 0914 had no
impact on the production of IFN-g upon allo-stimulation,
cytokine production of polyclonally stimulated T cells was
signiﬁcantly decreased by selective LMP7 inhibition with
ONX 0914 compared with vehicle treatment by approxi-
mately 50% (P ¼ .038, Figure 5).
Figure 5. Effect of ONX 0914 on the production of IFN-g by CD3/CD28 stim-
ulated T cells. B10BR lymph nodes were B cell depleted and 2  105 cells were
stimulated for 24 hours (at 37C and 5% CO2) with 5 mg/mL soluble puriﬁed
CD3 mAb and 5 mg/mL puriﬁed CD28 mAb, followed by ELISpot assay devel-
opment. Experiments were repeated twice with 4 to 8 wells per experiment,
and data are from a representative experiment. The Mann-Whitney U test
was used to compare spot counts between DMSO and ONX 0914 treatments.
*P < .05.
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Comparable GVHD Pathological Scoring with Control
Nontreated Mice
A separate set of BMT recipient mice were killed on days 5
and 12 post-BMT for pathological evaluation to determine if
the improved survival of ONX0 914eexposed groups
(Figure 1A) was associated with a concomitant histological
evidence of GVHD amelioration. The percent of initial body
weight (Figure 1B) was found to be equivalent between
groups (ie, ATBM versus ATBM þ ONX0914 and GVHD versus
ONX 0914 8 mg/kg [full dose, days 0, 1, and 2]), yet there was
a slight tendency for increased weight loss in groups exposed
to ONX 0914. Furthermore, quantitative histopathological
assessment of GVHD also indicated no difference between
treated and nontreated groups at either time point. Small
intestine, large intestine, and liver were analyzed and scored
by a trained pathologist based on villous blunting, crypt cell
hyperplasia, crypt cell apoptosis, and inﬂammation (small
intestine); crypt hyperplasia, crypt cell apoptosis, inﬂam-
mation, and Goblet cell depletion (colon); and bile duct
degeneration and inﬂammation (liver).
Scoring results and statistical comparisons between
groups can be found in Figure 6A. Figure 6B is a represen-
tative H & E histological image (day 12) of the small intestine,
colon, and liver for each group. As expected, GVHD scoring
was higher in mice challenged with T cells (GVHD and ONX
0914 groups) compared with mice receiving only ATBM cells
(ATBM and ATBM þ ONX 0914 groups), but only on day 12were the means signiﬁcantly different (ie, ATBM versus
GVHD, and ATBM þ ONX 0914 versus ONX 01914, P < .001).
Noticeably, on day 5, the mean scoring for the ONX 0914
group was lower, albeit not signiﬁcantly, compared with that
of GVHD mice (15.5 versus 14.25, respectively). This differ-
ence, however, was found to have reverted by day 12 (ie, ONX
0914 mean score ¼ 23.13 versus GVHD group ¼ 21). Of
interest, 1 mouse in the ATBM þ ONX 0914 group presented
with increased pathological scoring on day 12 as a result of
extensive inﬂammation and Goblet cell depletion (Figure 6A,
circled data point).
ONX 0914 Inhibits MHC Class IeRestricted Antigen
Presentation
It was reported that presentation of the endogenously
expressed LMP7-dependent male antigen UTY 246e254
epitope could be blocked by exposure to ONX 091475 [7].
Furthermore, in immunoproteasome triple knockout mice,
MHC class Ierestricted SIINFEKL peptide expression was
signiﬁcantly reduced compared with wild-type cells [15].
SIINFEKL peptide, the immunodominant epitope from oval-
bumin in the context of H-2Kb, is constitutively expressed on
transgenic C57BL/6-Tg(CAG-OVA)916Jen/J (B6-SIINFEKL)
mice and can elicit CD8þ Tcellespeciﬁc responses. Therefore,
we also tested the effect of ONX 0914 on SIINFEKL presen-
tation. To this end, RBC-lysed splenocytes from B6-SIINFEKL
mice were treated for 1 hour at 37C, as described, and
washed and incubated (37C and 5% CO2) for 3, 24, and 48
hours post-treatment before ﬂow cytometric analysis to
determine the percentage decrease in MHC-bound SIINFEKL
expression. As early as 3 hours post-treatment, SIINFEKL
expression was reduced by approximately 16% with respect
to DMSO exposure and peaked at 24 hours with an approx-
imate 27% reduction (Figure 7, P ¼ .039).
DISCUSSION
Proteasome inhibition has emerged as a useful anti-
cancer treatment for a number of hematological malig-
nancies, including multiple myeloma; solid tumors, such
as head and neck; and colorectal, prostate, and nonesmall
cell lung cancer [16]. Although proteasome inhibitors
represent a novel class of anticancer therapy with prefer-
ential induction of apoptosis in transformed cells [17,18],
their therapeutic potential has also been extended to T
cellemediated diseases because of their effects on cytokine
production and proliferation of lymphocytes as well as an-
tigen presentation. Bortezomib in particular, which targets
the constitutive proteasome and the immunoproteasome,
has been shown to prevent GVHD while preserving graft-
versus-leukemia (GVL) responses in tumor-bearing mice
after allogeneic BMT [8,9]. More recently, a number of novel
proteasome inhibitors preferentially targeting subunits of
the immunoproteasome have been developed to improve
the pharmacological proﬁle of these drugs while decreasing
unwanted toxicity [5,7,19,20]. In particular, the LMP7-
selective epoxyketone proteasome inhibitor ONX 0914 has
been shown efﬁcacious in various experimental models of
autoimmune disease, including arthritis [7], colitis [6], and
experimental autoimmune encephalomyelitis [3].
Based on these ﬁndings, we tested the effects of immu-
noproteasome suppression by ONX 0914 in the develop-
ment of GVHD using the B10.BR/CBA MHC-matched,
miHA-disparate BMT model. In this model, LMP7-selective
inhibition with ONX 0914 resulted in a modest but signiﬁ-
cant improvement in the survival rate of treated mice
Figure 6. Histological evidence of GVHD in CBA recipients treated with ONX 0914. CBA mice were exposed to lethal irradiation (11 Gy, split dose) and transplanted
with 2  106 ATBM cells alone or in combination with 1 107 CD8þ T cells from B10.BR donor mice. ONX 0914 was administered (full dose, 8 mg/kg) on days 0, 1, and
2 post-BMT as previously described, and mice were killed on days 5 and 12 post-BMT for pathological analyses of the small intestine, colon, and liver. (A) Quantitative
histopathological assessment of GVHD. Small intestine, colon, and liver were analyzed and scored based on villous blunting, crypt cell hyperplasia, crypt cell
apoptosis, and inﬂammation (small intestine); crypt hyperplasia, crypt cell apoptosis, inﬂammation, and Goblet cell depletion (colon); and bile duct degeneration and
inﬂammation (liver). Data points represent the mean scores of 3 to 4 mice  standard deviation per group. Statistical analysis was performed using 1-way ANOVA to
compare the mean of the cumulative GVHD scoring between groups, followed by Tukey’s multiple comparison test on individual pairs when ANOVA test was
statistically signiﬁcant (P < .05), ***P < .001, NS indicates not signiﬁcant. Circled data point highlights an animal in the ATBM þ ONX 0914 group on day 12 presenting
with increased pathological scoring. (B) Histological staining (H & E) of small intestine, large intestine, and liver on day 12 day post-BMT. Representative images from
small intestine (a-h), large intestine (i-p), and liver (q-x) of ATBM (a, b, e, f, i, j, m, n, q, r, u, v) and GVHD (c, d, g, h, k, l, o, p, s, t, w, x) mice either treated with vehicle
alone (a, c, e, g, i, k, m, o, q, s, u, w) or with ONX 0914 (b, d, f, h, j, l, n, p, r, t, v, x). Signiﬁcant villous blunting, crypt cell hyperplasia, and apoptosis are evident in GVHD
mice. Minimal to mild degree of inﬁltration of inﬂammatory cells were found in hepatic portal triads, but the epithelial integrity of the ducts were intact (red
arrowheads). Black arrowheads indicates the inﬂammatory foci. Black arrows and red arrows indicate representative apoptotic cells and mitotic ﬁgures, respectively.
Lower panels are 10 magniﬁcation of upper panels. Scale bar for upper and lower panels 200 mM and 20 mM, respectively.
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with decreased weight loss (Figure 1B) or amelioration
of pathological signs at either day 5 or 12 post-BMT
(Figure 6A), for all mice undergoing GVHD, irrespective of
treatment, manifested with comparable levels of GVHD
cumulative scoring (Figure 6A). That notwithstanding, on
day 5, mice treated with ONX 0914 exhibited a modest
decrease in pathological presentation, although not statis-
tically signiﬁcant (Figure 6A), suggesting the impact of
treatment might have taken place during or immediately
after drug exposure but that uponwithdrawal the beneﬁcial
effects of immunoproteasome suppression was lost.
Of interest, prolonged daily regimens on days 0 to 4; days
0, 2, 4, 6, 8, and 10 (data not shown); or split-dose daily
treatment to try to maintain constant levels of drug presence
failed to improve the survival of CBA recipient mice. In
addition, we also observed that mice in the ATBM control
group treated daily with ONX 0914 (days 0 to 4) presented
with greater weight loss at earlier time points, a trend that
continued up until the termination of the experiment
(Figure 1B), and that at least 1 mouse in the ATBM þ ONX
0914 group sampled for pathology had greater GVHD cu-
mulative scoring on day 12 (Figure 6A). Taken together, these
data support the notion of an early beneﬁt upon ONX 0914
administration in GVHD (<day 5) that was abrogated by day
12 and that extended treatment with this LMP7 inhibitor
may indeed be counterproductive.
Others have also reported [10,21] that the ability of bor-
tezomib to prevent GVHDwas subjected to its administrationimmediately after BMT (days 0 to 3) and that later treatment
of bortezomib, during GVHD development, or prolonged
administration of this inhibitor resulted in a GVHD-like
lethal toxicity resulting in marked acceleration of the dis-
ease. Of interest, this toxicity was correlated with an
increased presence of inﬂammatory cytokines (such as IL-1b,
IL-6, and TNFa), the expression of TNF-receptor 1 [10], and
allogeneic CD4þ T cells were found to be the key cell popu-
lation responsible for these side effects [8]. A more selective
inhibitor of the NF-kB pathway (PS-1145), however, did
induce toxicity in a murine model of GVHDwhen used either
at later time points post-BMTor in a prolonged regimen [21].
Furthermore, in our experimental model, a higher but less
selective dosage of ONX 0914 (10 mg/kg) also proved detri-
mental and resulted in a shorter MST (data not shown).
Although we did not conduct additional experiments to
elucidate the lack of GVHD improvement upon prolonged or
increased treatment, our combined results suggested that
selective targeting of the immunoproteasome provided no
outstanding advantage compared with bortezomib, which
when administered early on after transplant in the BALB/
c/B6 MHC-mismatch model [9] resulted in a signiﬁcant
increase in the MSTof recipient mice or complete abrogation
of GVHD, depending on the number of transplanted donor T
cells.
Next, we investigated other potential mechanisms by
which ONX 0914 could have halted GVHD progression. In this
regard, we tested its effects on the production of IFN-g by
allogeneic Tcells in B10.BR anti-CBA aswell as B10.BR anti-B6
Figure 7. Effect of ONX 0914 on SIINFEKL expression. RBC-lysed splenocytes from C57BL/6-Tg(CAG-OVA)916Jen/J mice were treated with ONX 0914 (300 nM) or
vehicle (DMSO, .1%) for 1 hour. Cells were incubated (at 37C and 5% CO2) for 3 hours, 24 hours, and 48 hours post-treatment and analyzed using ﬂow cytometry to
determine the percentage of SIINFEKL expression. To minimize readout skewing due to cell death, cells were subjected to gradient separation with lympholyte M to
obtain puriﬁed viable cells. (A) The percentage decrease was calculated as ([%SIINFEKL in DMSO-%SIINFEKL in ONX 0914 treated splenocytes]/[%SIINFEKL in DMSO]).
Experiments were repeated twice, with 2 to 3 spleens per condition. Statistical analysis was performed using 1-way ANOVA to compare percentage decrease in
SIINFEKL expression at different time points followed by Tukey’s multiple comparison test on individual pairs when ANOVA test was statistically signiﬁcant (P < .05).
By 3 hours the decrease in SIINFEKL expression was 16.31%  2.4%, at 24 hours it peaked at 26.94%  4.10%, and by 48 hours by 23.47%  5.03%. *P < .05 (between 3
and 24 hours). (B) Representative histogram plot on the effect of ONX 0914 on SIINFEKL expression. At 24 hours the percentage decrease in SIINFEKL expression was
25.5% (from 74.5% in DMSO versus 55.5% in ONX 0914). (C) The mean ﬂuorescence intensity (MFI) was also considerably decreased after ONX 0914 treatment. In
region D the decrease was of 26.16%, whereas the entire MFI shifted 41.93%.
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lator cells were treated before culture. Also, we varied the
treatment sequence so that irradiation of stimulator cells
was performed either before or after treatment to emulate
the in vivo condition wherein administration was performed
post-irradiation (ie, ﬁrst dose was given post-irradiation and
after ATBM and lymphocyte transplantation. Then, we
postponed the use of treated stimulators for 24 hours to
evaluate if maximal effects could be achieved by pretreat-
ment before culture. The results from these experiments
indicated that ONX 0914 preferentially modulated stimulator
cells, whereas treatment of responder cells before MLC had
no effect on IFN-g production (Figure 2B); and that a 24-hour
lapse between the exposure of stimulator cells to ONX 0914before initiation of the MLC did not completely abrogate the
production of IFN-g by allogeneic B10.BR T cells against
treated B6 splenocytes. However, the data suggested that it
provided more suppression (w77% versus 60% when cells
were plated immediately after treatment).
To assert the speciﬁcity of LMP7 immunoproteasome
inhibition, we compared the effects of ONX 0914 with
PR-825 (an inhibitor of the constitutive proteasome). The
results indicated that allogeneic responses in both MHC-
mismatched and miHA-disparate models tested could be
suppressed upon ONX 0914 treatment of stimulator cells but
remained unaffected in PR-825 treated cultures (Figures 3
and 4). Furthermore, because both GVHD and GVL re-
sponses in the B10.BR/CBA BMT model are mediated by
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of CD8þ B10.BR T cells in MLCs against ONX 0914 or
PR-825etreated CBA splenocytes and conﬁrmed that only
LMP7-speciﬁc inhibition led to a decreased production of
IFN-g by this population (Figure 4).
ONX 0914 has been shown to block cytokine production
by activated lymphocytes [6,7,23]. We thus investigated
whether ONX 0914 treatment would result in a consequent
reduction of IFN-g production by allo-stimulated responder
T cells but found no signiﬁcant difference. At the same time,
we corroborated that ONX 0914etreated CD3/CD28 stimu-
lated T cells produced signiﬁcantly less IFN-g (w50% less),
similar to that reported in the literature [7] (Figure 5). As a
possible explanation to the observed discrepancy between
allogeneic and polyclonal responses, we hypothesize that
either allogeneic and polyclonal stimulation work differen-
tially on immunoproteasome activity of T cells or that the
effect of a 1-hour exposure to ONX 0914 on alloreactive T
cells was lost or rendered ineffective because of the much
slower activation process associated with normal antigen
recognition (which may take 6 to 18 hours to occur).
Although this latter scenario would have also likely affected
the MLC in which stimulator cells alone were treated, we
speculate that the exposure of splenocytes to high-dose
irradiation (15 Gy) may have hindered the reinstitution of
the inhibited immunoproteasome activity, accounting for the
observed results. Similarly, in vivo administration of ONX
0914 may have had a minimal effect on allo-antigen stimu-
lated T cells. On the other hand, effects on recipient antigen-
presenting cells were more impactful although limited
by the proteosomal reconstitution of radio-resistant host
cells capable of reinstating LMP7 activity after cessation of
treatment.
Finally, because the immunoproteasome can shape both
endogenous and virally derived MHC class Ierestricted
antigen presentation [7,20,24], we investigated the effects of
ONX 0914 on the endogenously expressed SIINFEKL peptide.
Although to the best of our knowledge there has been
no study demonstrating the LMP7-dependency of the
OVA257e264 epitope, we decided to use splenocytes from
transgenic B6-SIINFEKL mice because this peptide is known
to generate CD8þ T responsesdthe population largely
responsible for GVHD in the B10.BR/ CBA model [22].
Interestingly, we found that the percentage decrease of
SIINFEKL expression peaked at 24 hours after a 1-hour
exposure to ONX 0914 and that this decrease was less
prominent by 48 hours (Figure 7).
In addition to down-regulation of IFN-g production,
ONX 0914 can inhibit IL-23 and TNF-a production, among
other cytokines [6,7,23], in an NK-kBeindependent manner.
Reduction of TNF-a in particular was shown to be associated
with bortezomib-induced amelioration of GVHD [9], sug-
gesting that reduction of cytokines associated with the
development of this disease is a plausible mechanism for the
improved survival of CBA recipients in our model. Of note,
a pilot proliferation study (Supplemental Figure 1) also
showed that donor T cells displayed a lower proliferative
tendency when recipient mice were treated with ONX 0914
or bortezomib. Particularly, ONX 0914 had a greater per-
centage of eFluor670high cells. Nevertheless, bortezomib
had by far a lower ratio of eFluor670low/(eFluor670low þ
eFluor670high) cells in both the CD4þ and CD8þ populations
but particularly in the CD8 group, suggesting, as previously
described, that bortezomib induces cell apoptosis of allor-
eactive and dividing T cells [9]. Likewise, we also noted thatONX 0914 exposure (ie, 1 hour in vitro treatment as
described) did not induce cell death (data not shown),
as previously reported to be the case after in vivo adminis-
tration in naive mice [7]. Furthermore, we did not see a
reduction of IFN-geproducing spot counts when Tcells alone
were treated beforeMLC; therefore, we believe the ONX 0914
treatments (both in vitro and in vivo) did not induce signif-
icant apoptosis of alloreactive T cells.
Together with the fact that proteasome-mediated prote-
olysis is responsible for the generation of immunogenic
epitopes presented by MHC class I molecules, necessary
to activate antigen-speciﬁc CD8þ T cells [24], our data sup-
port that LMP7 inhibition in the context of BMT modulates
allogeneic responses by decreasing endogenous miHA
presentation and that the consequential reduction in allo-
stimulation and cytokine production reduces GVHD devel-
opment. Finally, in lieu of its potential effects on antigen
presentation, immunoproteasome inhibition will also need
to be tested in tumor-bearing mice to ensure the beneﬁts
presented here for GVHD are not detrimental to the GVL
potential of the transplant.
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